The Food and Drug Administration's Center for Drug Evaluation and Research wants ideas on how to link previously "siloed" systems for gathering data in an effort to quicken the pace of clinical innovation.
Provider-focused approaches to scheduling and failure to appropriately use nurse practitioners and physician assistants are among the reasons timely access to care remains a problem in the U.S., according to an Institute of Medicine report.
Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data posted to the CMS' Open Payments website.
In an industry that's been rapidly consolidating, Catholic Health Initiatives has had a particularly rapid growth trajectory. The Englewood, Colo.-based system has struggled to contain costs associated with acquiring new hospitals. But CHI is improving in its core business, which could bode well...
A report from the Institute of Medicine suggests revamping the national strategy for cardiac arrest to standardize surveillance, coordination, data collection, public education and the sharing of best practices pertaining to the condition.
The home-care sector is keeping an eye out for an expected move by the White House to make up to 5 million more people eligible for overtime pay. Some say it could benefit fee-based employees while others believe it could cause employers to scale back on hiring specialized workers.
The U.S. Supreme Court will hear a case asking it to limit the power of public unions to collect fees from nonmembers. The case could threaten the finances and membership efforts of unions that represent healthcare workers at publicly owned providers.
Ascension intends to sell two Pacific Northwest hospitals to for-profit Capella Healthcare for undisclosed terms.
Leading biotech firm Celgene Corp. will pay $1 billion to enter into a 10-year collaboration with Juno Therapeutics. The move broadens the company's cancer drug portfolio by gaining access to Juno's budding pipeline of oncology immunotherapies.
Federal prosecutors have reached a $20.3 million civil settlement with Community Health Network to resolve allegations of overbilling for surgeries.
The makers of the potent painkiller OxyContin have pulled out of a federal meeting to review the company's harder-to-abuse version of the much-debated drug.
The U.S. Supreme Court will hear a case next term on whether a self-funded insurer should have to turn over certain information to the state of Vermont, a case that could have far-reaching implications over who controls certain healthcare data.